Premium
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries
Author(s) -
HOLM JOHAN,
ZÖLLER BENGT,
BERNTORP ERIK,
ERHARDT LEIF,
DAHLBÄCK BJÖRN
Publication year - 1996
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1046/j.1365-2796.1996.470808000.x
Subject(s) - medicine , factor v , odds ratio , myocardial infarction , mutation , risk factor , population , gastroenterology , etiology , factor v leiden , venous thrombosis , thrombosis , genetics , gene , environmental health , biology
Objective. Haemostatic imbalance may be an aetiological factor in the development of acute coronary syndromes. Inherited resistance to activated protein C (APC) is a common disorder associated with hypercoagulability and lifelong risk of venous thrombosis. APC resistance is due to a single mutation in the gene coding for coagulation factor V (FV:Q 506 ). To test the importance of the FV:Q 506 mutation in premature myocardial infarction (MI), its prevalence was investigated in Swedish patients with MI before the age of 50 years. Design, setting and subjects. In a retrospective case‐control study, the FV:Q 506 mutation was investigated in 101 survivors of MI (79 men, 22 women) and in 101 healthy sex‐ and age‐matched controls. Main outcome measure. The prevalence of FV:Q 506 mutation. Results. The FV:Q 506 mutation was found in 18% of patients versus 11% of controls ( P =0.16). The mutation was significantly more frequent amongst male patients than amongst controls (23 vs. 10%; P =0.03), the calculated odds ratio being 2.6 (95% CI, 1.1–6.4). Conclusion. The high prevalence of the FV:Q 506 mutation found amongst Swedish MI patients, especially amongst men, is noteworthy, and calls for further studies on the outcome of MI in APC‐resistant patients. The prevalence of the FV:Q 506 mutation in controls is higher than figures reported from other countries, suggesting that at least 10% of the Swedish population are carriers of a congenital prothrombotic disorder.